ClinicalTrials.gg
Status unknownNCT01899209PRO-RESTUpdated Jun 27, 2014

Surgical Treatment of Obstructed Defecation Syndrome

An interventional study of STARR and Laparoscopic Ventral Rectopexy in Sensation of Inadequate Defecation, Rectal Prolapse and Rectocele, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Status unknown at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-27.

Sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2014), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Obstructed Defecation is a profoundly disabling condition. Many different surgical procedures has been introduced to treat patients affected by this disease. The most used are STARR and ventral rectopexy. Because of the heterogenity of studies and overall the lack of comparison trials, there is no accepted standard surgical treatment.PRO-REST aimed to compare these two procedures (STARR and Ventral Rectopexy) evaluating functional and anatomical results.

02

Conditions studied

  • Sensation of Inadequate Defecation
  • Rectal Prolapse
  • Rectocele

Keywords

  • Obstructed Defecation
  • Rectal rectocele
  • Intussusception
  • STARR
  • Ventral Rectopexy
03

In context

Rectal Prolapse

55 studies on the registry are indexed under Rectal Prolapse; 12 are open to participants now.

This study's planned enrollment of 40 is below the median of 55 across 34 interventional studies indexed under Rectal Prolapse.

Browse Rectal Prolapse studies →

Lead sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna is the lead sponsor of 511 studies on the registry; 287 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients affected by Obstructed Defecation with ODS score >11
  • Symptomatic rectal Intussusception and/or defecographic finding of rectocele>2 cm
  • Failure of at least 6 months of medical therapy
  • Exclusion of neoplasm by rectosigmoidoscopy/colonoscopy

Exclusion criteria

Exclusion Criteria:

  • Patients affected by complete rectal prolapse
  • Patients affected by slow transit constipation
  • Patients affected by anismus
  • Patients affected by pelvic organ prolapse
  • Patients with previous rectal or anal surgery
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Group A

    STARR

    Procedure: STARR

  • Experimental
    Group B

    Laparoscopic ventral Rectopexy

    Procedure: Laparoscopic Ventral Rectopexy

Interventions

  • ProcedureSTARR
  • ProcedureLaparoscopic Ventral Rectopexy
06

What researchers measure

Primary outcomes

  1. Functional result

    comparison between Obstructed Defaecation Syndrome (ODS) score before and 12 months after surgery

    Time frame: 12 months

Secondary outcomes

  1. Anatomical result

    Comparison of clinical and radiological data before and 12 months after surgery

    Time frame: 12 months

Other outcomes

  1. Quality of life and safety

    Comparison of Constipation-Related Quality of Life questionnaire (CRQoL) before and 12 months after surgery Comparison of morbidity and mortality rate between the two procedures

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • University Hospital
    Bologna, 40138, Italy
    Recruiting
    • Dajana Cuicchi, MD PhD · Contactcuicchidajana@yahoo.it · 0516363236
    • Dajana Cuicchi, MD PhD · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013 and a primary completion of Aug 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2013
First posted
Jul 15, 2013
Start
Aug 2013
Primary completionEst.
Aug 2015
Last update
Jun 27, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01899209
Responsible party
Dajana Cuicchi (Dr Dajana Cuicchi, IRCCS Azienda Ospedaliero-Universitaria di Bologna) — Principal investigator
First posted
Jul 15, 2013
Start date
Aug 2013
Primary completion
Aug 2015 (estimated)
Last update
Jun 27, 2014

Study contacts

Dajana Cuicchi, MD PhD
Contact
dajana.cuicchi@aosp.bo.it
0516363236 ext. 0039

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion